| Study | Reason for Exclusion |
|---|---|
| Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol. 2006 Sep 20;24(27):4441-7. | Mixed population including metastatic patients |
| Aigner KR, Gailhofer S, Kopp S. Regional versus systemic chemotherapy for advanced pancreatic cancer: a randomized study. Hepatogastroenterology. 1998 Jul-Aug;45(22):1125-9. | Mixed population including metastatic patients |
| Ambe C, Fulp W, Springett G, Hoffe S, Mahipal A. A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer. J Gastrointest Cancer. 2015 Sep;46(3):284-90. | Systematic review not relevant to PICO: references have been checked |
| Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, et al. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN13001. J Clin Oncol. 2008 Aug 1;26(22):3695-701. | Mixed population including metastatic patients |
| Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002 Jul 15;87(2):161-7. | Mixed population including metastatic patients |
| Bukowski RM, Balcerzak SP, O’Bryan RM, Bonnet JD, Chen TT. Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer A Southwest Oncology Group study. Cancer. 1983 Nov 1;52(9):1577-82. | Mixed population including metastatic patients |
| Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo. Gemcitabine versus FLEC regimen given intra-arterially to patients with nresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. | Mixed population including metastatic patients |
| Chen J, Xiao-Zhong G, Qi XS. Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. J Immunol Res. 2017:8282391. | This review included 25 articles, which are mostly not respondent to the inclusion criteria (no study design, no comparative evidence, no English). Therefore references have been checked for relevant studies |
| Chen Y, Sun XJ, Jiang TH, Mao AW. Combined radiochemotherapy in patients with locally advanced pancreatic cancer: a meta-analysis. World J Gastroenterol. 2013 Nov 14;19(42):7461-71. | Systematic review not relevant to PICO: references have been checked |
| Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010 Apr 1;28(10):1645-51. | Mixed population including metastatic patients |
| Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25. | Mixed population including metastatic patients |
| Dababou S, Marrocchio C, Rosenberg J, Bitton R, Pauly KB, et al. A meta-analysis of palliative treatment of pancreatic cancer with high intensity focused ultrasound. J Ther Ultrasound. 2017;5:9. | This review included 23 articles, which are mostly not respondent to the inclusion criteria (no study design, no comparative evidence, no English). Therefore references have been checked for relevant studies |
| Fegrachi S, Besselink MG, van Santvoort HC, van Hillegersberg R, Molenaar IQ. Radiofrequency ablation for unresectable locally advanced pancreatic cancer: a systematic review. HPB (Oxford). 2014 Feb;16(2):119-23. doi: 10.1111/hpb.12097. | Review including evidence not matching the inclusion criteria: references have been checked |
| Girelli R, Giardino A, Frigerio I, Salvia R, Partelli S, Bassi C. Survival after radiofrequency of stage III pancreatic carcinoma: a wind of change? HBP. 2011;13(Suppl. 2):15 | Conference abstract |
| Gonçalves A, Gilabert M, François E, Dahan L, Perrier H, Lamy R, Re D, Largillier R, Gasmi M, Tchiknavorian X, Esterni B, Genre D, Moureau-Zabotto L, Giovannini M, Seitz JF, Delpero JR, Turrini O, Viens P, Raoul JL. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol. 2012 Nov;23(11):2799-805. | Mixed population including metastatic patients |
| Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O,Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Boige V, Bérille J, Conroy T. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients withmetastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2013 Jan 1;31(1):23-9. | Mixed population including metastatic patients |
| Han GH, Yin ZX, Meng XJ, He CY, Zhang HB, Sun AH, Wu KC, Ding J, Fan DM. Prospective randomized clinical trial of two drug delivery pathway in the treatment of inoperable advanced pancreatic carcinoma. Chin J Dig Dis. 2006;7(1):45-8. | Mixed population including metastatic patients |
| Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007 Jun 1;25(16):2212-7. | Mixed population including metastatic patients |
| Huang D, Fang J, Luo G. Meta-analysis of gemcitabine and cisplatin combination chemotherapy versus gemcitabine alone for pancreatic cancer. J Cancer Res Ther. 2016;12(Supplement):104-108. | References have been checked for relevant studies, no new evidence was identified |
| Ierardi AM, Lucchina N, Petrillo M, Floridi C, Piacentino F, et al. Systematic review of minimally invasive ablation treatment for locally advanced pancreatic cancer. Radiol Med. 2014 Jul;119(7):483-98. | Systematic review not relevant to PICO: references have been checked |
| Ji Z, Wang Y, Chen X, Wu T. Peripancreatic artery ligation and artery infusion chemotherapy for advanced pancreatic carcinoma. Chin Med J (Engl). 2003 Jan;116(1):89-92. | Mixed population including metastatic patients |
| Keane MG, Bramis K, Pereira SP, Fusai GK. Systematic review of novel ablative methods in locally advanced pancreatic cancer. World J Gastroenterol. 2014 Mar 7;20(9):2267-78. doi: 10.3748/wjg.v20.i9.2267. | Review including evidence not matching the inclusion criteria: references have been checked |
| Kindler HL, Ioka T, Richel DJ, Bennouna J, Létourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM, Wasan HS, Trask PC, Bycott P, | Mixed population including metastatic patients |
| Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer. 2012 Jun;48(9):1283-92. | Mixed population including metastatic patients |
| Matsui Y, Nakagawa A, Kamiyama Y, Yamamoto K, Kubo N, Nakase Y. Selective thermocoagulation of unresectable pancreatic cancers by using radiofrequency capacitive heating. Pancreas. 2000;20:14–20. | Mixed population including metastatic patients |
| Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20;25(15):1960-6. | Mixed population including metastatic patients |
| Oster MW, Gray R, Panasci L, Perry MC. Chemotherapy for advanced pancreatic cancer A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer. 1986 Jan 1;57(1):29-33. | Mixed population including metastatic patients |
| Shamseddine AI, Khalifeh MJ, Mourad FH, Chehal AA, Al-Kutoubi A, Abbas J, Habbal MZ, Malaeb LA, Bikhazi AB. Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. Clin Pharmacokinet. 2005;44(9):957-67. | Mixed population including metastatic patients |
| Singh V, Varshney S, Sewkani A, Varshney R, Deshpande G, Shaji P, et al. Radiofrequency ablation of unresectable pancreatic carcinoma: 10-year experience from single centre. Pancreatology. 2011;11(Suppl. 1):52. | Conference abstract |
| Spiliotis JD, Datsis AC, Michalopoulos MV, Kekelos SP, Vaxevanidou A, Rogdakis AV, et al. Radiofrequency ablation combined with palliative surgery may prolong survival of patients with advanced cancer of the pancreas. Langenbecks Arch Surg. 2007;392:55–60 | Mixed population including metastatic patients |
| Su D, Jiao SC, Wang LJ, Shi WW, Long YY, et al. Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. Tumour Biol. 2014 Mar;35(3):2313-8. | Mixed population including metastatic patients |
| Sudo K, Ishihara T, Hirata N, Ozawa F, Ohshima T, et al. Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer. Cancer Chemother Pharmacol. 2014 Feb;73(2):389-96. | Mixed population including metastatic patients |
| Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016 Jun;17(6):801-10. | Systematic review not relevant to PICO: references have been checked |
| Sultana A, Tudur Smith C, Cunningham D, Starling N, Tait D, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer. 2007 Apr 23;96(8):1183-90. | Systematic review not relevant to PICO: references have been checked |
| Topham C, Glees J, Coombes RC. Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas. Oncology. 1993 Apr;50 Suppl 1:78-80. | Mixed population including metastatic patients |
| Ulrich-Pur H, Raderer M, Verena Kornek G, Schüll B, Schmid K, et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer. 2003 Apr 22;88(8):1180-4. | Mixed population including metastatic patients |
| Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ: Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009, 27(13):2231–7. | Mixed population including metastatic patients |
| Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703. | Mixed population including metastatic patients |
| Wang X, Ni Q, Jin M, Li Z, Wu Y, et al. Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer. Zhonghua Zhong Liu Za Zhi. 2002 Jul;24(4):404-7. | Mixed population including metastatic patients |
| Wu Y, Tang Z, Fang H, Gao S, Chen J, Wang Y, et al. High operative risk of cool-tip radiofrequency ablation for unresectable pancreatic head cancer. J Surg Oncol. 2006;94:392–395. | Mixed population including metastatic patients |
| Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, Okusaka T, Ueno H, Boku N, Fukutomi A, Ishii H, Ohkawa S, Furukawa M, Maguchi H, Ikeda M, Togashi Y, Nishio K, Ohashi Y. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci. 2015 Jul;106(7):883-90. doi: 10.1111/cas.12674. | Mixed population including metastatic patients |
| Yang YF, Cao XH, Bao CE, Wan X. Concurrent radiotherapy with oral fluoropyrimidine versus gemcitabine in locally advanced pancreatic cancer: a systematic review and meta-analysis. Onco Targets Ther. 2015 Nov 9;8:3315-22. | Systematic review not relevant to PICO: references have been checked |
| Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev. 2006 Jul 19; | Systematic review not relevant to PICO: references have been checked |
| Zhu CP, Shi J, Chen YX, Xie WF, Lin Y. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a metaanalysis. Radiother Oncol. 2011 May;99(2):108-13. | Systematic review not relevant to PICO: references have been checked |
From: Appendix G, Excluded studies
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.